Immunovant FY2025 EPS Estimate Lowered by Lifesci Capital

Immunovant, Inc. (NASDAQ:IMVT) – Lifesci Capital dropped their FY2025 earnings estimates for Immunovant in a report released on Sunday, February 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($2.64) per share for the year, down from their previous estimate of ($2.36). The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant’s Q4 2025 earnings at ($0.56) EPS.

Several other research analysts have also commented on IMVT. Wolfe Research lowered shares of Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. Wells Fargo & Company decreased their price target on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price objective on shares of Immunovant in a research report on Friday, February 7th. Bank of America decreased their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald upgraded Immunovant to a “strong-buy” rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $45.90.

Immunovant Stock Down 3.2 %

Shares of Immunovant stock opened at $19.78 on Wednesday. The business has a 50 day moving average of $22.83 and a 200 day moving average of $27.10. Immunovant has a 52 week low of $19.07 and a 52 week high of $39.55. The company has a market cap of $3.36 billion, a PE ratio of -7.55 and a beta of 0.65.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08).

Insider Buying and Selling

In other Immunovant news, insider Michael Geffner sold 2,657 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $23.59, for a total value of $62,678.63. Following the sale, the insider now owns 132,314 shares in the company, valued at $3,121,287.26. The trade was a 1.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eva Renee Barnett sold 4,105 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total value of $98,930.50. Following the transaction, the chief financial officer now owns 327,064 shares of the company’s stock, valued at approximately $7,882,242.40. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,510 shares of company stock worth $656,886. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Immunovant

Large investors have recently added to or reduced their stakes in the company. KBC Group NV grew its holdings in shares of Immunovant by 46.2% in the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock valued at $55,000 after purchasing an additional 612 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Immunovant during the fourth quarter valued at $76,000. Assetmark Inc. grew its stake in shares of Immunovant by 73.8% in the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after buying an additional 1,228 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Immunovant by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock worth $148,000 after buying an additional 934 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Immunovant during the 4th quarter valued at about $221,000. Institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.